anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Targeted temperature management (TTM) is considered to be a neuroprotective strategy during cardiopulmonary bypass (CPB) assisted procedures, possibly through the activation of cold shock proteins. We therefore investigated the effects of mild compared with deep hypothermia on the neuroinflammatory response and cold shock protein expression after CPB in rats.
METHODS: Wistar rats were subjected to 1 hr of mild (33 °C) or deep (18 °C) hypothermia during CPB or sham procedure. PET scan analyses using TSPO ligand [11C]PBR28 were performed on day 1 (short-term) or day 3 and 7 post-procedure (long-term) to assess neuroinflammation. Hippocampal and cortical samples were obtained at day 1 in the short-term group and at day 7 in the long-term group. mRNA expression of M1 and M2 microglia associated cytokines was analysed with RT-PCR. Cold shock protein RNA-binding motive 3 (RBM3) and tyrosine receptor kinase B (TrkB) receptor protein expression were determined with Western Blot and quantified.
RESULTS: In both groups target temperature was reached within an hour. Standard uptake values (SUV) of [11C]PBR28 in CPB rats at 1 day and 3 days were similar to that of sham animals. At 7 days after CPB the SUV was significantly higher in amygdala and hippocampal regions of the CPB 18 °C group as compared to the CPB 33 °C group. No differences were observed in the expression of M1 and M2 microglia-related cytokines between TTM 18 °C and 33 °C. RBM3 protein levels in cortex and hippocampus were significantly higher in CPB 33 °C compared to CPB 18 °C and sham 33 °C, at day 1 and day 7, respectively.
CONCLUSIONS: TTM at 18 °C increased the neuroinflammatory response in amygdala and hippocampus compared to TTM at 33 °C in rats undergoing a CPB procedure. Additionally, TTM at 33 °C induced increased expression of TrkB and RBM3 in cortex and hippocampus of rats on CPB compared to TTM at 18 °C. Together, these data indicate that neuroinflammation is alleviated by TTM at 33 °C, possibly by recruiting protective mechanisms through cold shock protein induction.
The present invention relates to the preparation of surface cleaning and protection compositions. A typical embodiment of this invention may be a lotion, a soap, a cream, an aerosol, a gel, a medicinal lotion, a fabric cleanser, a furniture polish, an automobile polish, and a cleanser for other solid surfaces. The use of polyhederal oligomeric silsequioxane (POSS) allows greater flexibility in delivering active agents to a surface as well as for surface protection from irritants. The current invention discloses compositions for a variety of applications ranging from skin care, home hygiene, health care, entertainment, and children training/education. The compositions may provide molecular-level benefits, form breathable protection layers on a surface (e.g. skin), provide UV protection, provide foaming effects or allow users (consumers) to know when or if the cleaning is complete.
BCG was developed as a vaccine against tuberculosis (TB), but many studies have now confirmed its ability to induce potent protection against other infectious diseases in children. It has recently been shown that this may be linked to increased response of the innate immune system to several non-specific pathogens after BCG exposure, so called 'innate immune training'. This training ability of BCG has been shown for children and young adults. However, to our knowledge, no studies on the ability of BCG to induce innate immune training in adults \>50 years of age have been conducted. Immune training in elderly is of interest since with increasing age, the immune system gets weaker, and responds less adequately to a number of infections, for instance influenza. Thus, if BCG is able to stimulate the innate immune system in mature adults as well, it could potentially reduce the risk of serious infections in elderly.

To investigate whether BCG has innate immune training effects in mature adults, a randomized pilot study of 40 adults \>50 years of age in Guinea-Bissau will be conducted. The Bandim Health Project has conducted multiple large-scale RCT's and demographic surveillance. HIV negative adults \>50 years of age in a recent HIV survey are eligible for the present study. They will be checked for clinical signs of TB and an HIV test will be preformed before enrolment. Exclusion criteria are BCG vaccination within the last 10 years, illness within the last 14 days, clinical signs of active TB, and/or a positive HIV test. Those who are overtly ill will be treated or referred to hospital if needed. Those with signs of TB will be referred to the TB hospital for further examinations. Those who have become HIV positive since they were tested in the survey will receive immediate counselling and be referred to the HIV clinic.

Participants will be randomized to either BCG vaccination or placebo. To test the innate immune system blood will be withdraw 3 times: before the intervention, 2 weeks and 3 months after the intervention. There is a maximum of 10 ml blood each time, plus 3 ml the first time for the Quantiferon. This is a small volume, with a maximum of 33 ml and should not cause any problems for participants. Quantiferon results will be used as a baseline to test if participants are sensitized to mycobacterium Tuberculosis. In the blood, the innate immune training effects of BCG we will investigated by studying how the immune cells respond when they are stimulated with bacteria or other pathogens, which can cause serious infections. Provided that BCG shows induced innate immune training in adults \>50 years of age, a large randomized control trial will follow to see if BCG vaccination reduces the number of acute infections in adults \>50 years of age in Guinea-Bissau.
An ion-exchange membrane electrolysis device includes an ion-exchange membrane electrolytic cell and an integrally formed integrated flow channel device. The ion-exchange membrane electrolytic cell generates a gas comprising hydrogen. The integrated flow channel device has a first setting structure, a water tank structure, a gas flow channel system and a water flow channel system. The water tank structure accommodates water. The first setting structure is configured for removably fixing the ion-exchange membrane electrolytic cell to the integrated flow channel device. The water flow channel system connects the water tank structure and the first setting structure for inputting the water in the water tank structure into the ion-exchange membrane electrolytic cell. The gas flow channel system is connected to the first setting structure for receiving and transporting the gas comprising hydrogen. Therefore, the present invention integrates functionally independent pathways, decreases pipeline connections, reduces volume of device, and improves safety of operation.
Advanced neuroendocrine tumors (NETs) are associated with a poor prognosis. A regimen of 4 cycles of 177Lu-DOTATATE has been shown to improve both progression-free survival (PFS) and overall survival (OS) in patients with advanced NETs. To the best of our knowledge, this is the first study in the United States to evaluate the effectiveness and safety of additional cycles of 177Lu-DOTATATE therapy in patients with progressive NETs. Methods: This was a retrospective chart review of adults with advanced NETs. The patients had undergone initial treatment with up to 4 cycles of 177Lu-DOTATATE and, after disease progression and a period of at least 6 mo since the end of the initial treatment, were retreated with at least 1 additional cycle at a single center (2010-2020). Patient characteristics, treatment patterns, and clinical outcomes were evaluated descriptively. Response was evaluated according to RECIST 1.1; toxicity was defined using criteria from Common Terminology Criteria for Adverse Events, version 5.0. Kaplan-Meier plots were used to evaluate PFS and OS. Results: Of the 31 patients who received 177Lu-DOTATATE retreatment, 61% were male and 94% were White. Overall, patients received a median of 6 cycles (4 initial cycles and 2 retreatment cycles), and the mean administered activity was 41.9 GBq. Two patients also went on to receive additional retreatment (1 and 2 cycles, individually) after a second period of at least 6 mo and progression after retreatment. Best responses of partial response and stable disease were observed in 35% and 65% of patients after the initial treatment and 23% and 45% of patients after retreatment, respectively. The median PFS after the initial treatment was 20.2 mo and after retreatment was 9.6 mo. The median OS after the initial treatment was 42.6 mo and after retreatment was 12.6 mo. Hematologic parameters decreased significantly during both the initial treatment and retreatment but recovered such that there was little difference between the values before the initial treatment and before the retreatment. Clinically significant hematotoxicity occurred in 1 and 3 patients after the initial treatment and retreatment, respectively. No grade 3 or 4 nephrotoxicity was observed. Conclusion: Retreatment with 177Lu-DOTATATE after progression appeared to be well tolerated and offered disease control in patients with progressive NETs after initial 177Lu-DOTATATE treatment.
Background and Objectives: A polymorphism in the promoter region of the IL-6 gene would influence the level of IL-6 expression in patients with HCV, resulting in a pro-inflammatory response. Few studies have shown the association between -174G>C (rs1800795) and -1363G>T (rs2069827) polymorphisms and HCV infection, and their results have been contradictory. There are no data published in our population to study such an IL-6 stimulus against HCV infection and its impact on RNA secondary structure. Therefore, we isolated human subjects from the province of Punjab, Pakistan. The objective was to screen for IL-6 gene promoter polymorphisms -174G/C and -1363G/T and those correlated with serum concentrations of IL-6 in patients with HCV and compared with a control. Materials and Methods: In conventional PCR, measurement of serum IL-6 by CLIA and statistical analysis were performed to observe the genotype association studies. By integrating bioinformatics and computational tools, our study aimed to provide a comprehensive understanding of how variations in the promoter region of IL-6 may have functional implications on gene expression. Results: The -174G>C and -1363G>T genotypes in the promoter region of patients with HCV were in strong allelic association (Δ = 0.97, p < 0.001). Interestingly, the bioinformatics analysis was well aligned with our experimental data. Conclusions: Based on the data, it can be inferred that IL-6 gene promoter polymorphisms are important in the dysregulation of IL-6 levels in patients with HCV.
The invention relates to the technical field of bioengineering, and particularly relates to a novel technology of a preparation process of a transfer factor. The preparation process comprises the following steps of: adding normal saline into a treated spleen of a laying hen, wherein the amount of the treated spleen of the laying hen is equal to that of the normal saline; homogenating by using a colloid mill and then adjusting a PH (Potential of Hydrogen) value to 3.5 at a temperature of 20 DEG C; repeatedly freezing and thawing for three times at a temperature of -20 to -25 DEG C; centrifuging and taking supernate for later use; taking residue and then grinding again, adjusting the PH value, repeatedly freezing and thawing for three times, centrifuging and taking supernate, and mixing the supernates; and carrying out virus inactivation and ultrafiltration, adjusting the PH value to 7.0, filtering and sterilizing, and the like to obtaining a transfer factor oral solution of the spleen of the laying hen. The transfer factor is mixture consisting of bioactive polypeptide and nucleotide, and has the functions of transferring a cellular immune function of donor cells to recipient cells, non-specifically enhancing ordinary cellular immunity, and improving an immunologic function of a receptor. The transfer factor is safe and non-toxic and is a novel immunomodulator. The transfer factor is mainly used for treating viral infections and autoimmune diseases. The immune effect can be obviously enhanced by using the transfer factor with a vaccine in a matched manner.
A method for generating a medical report includes receiving patient image data from a user in response to displaying a patient image to the user that is retrieved from a server. The user enters patient image data directly into an image time series template. The patient image data, in one embodiment, pertains to measurements of objects (both target and non-target) of the patient shown in the patient image. Patient image data is then extracted from the image time series template and data is calculated pertaining to an object (e.g., a lesion) in the image based on the extracted data and the location of the extracted data in the image time series template. The calculated results are presented for review by a user. In response to the user approving the results, a report of the results is generated.
PROBLEM TO BE SOLVED: To obtain an inhibitor of cytokines such as interleukin-1β, excellent in inhibiting activities against specific three kinds of cytokines and hardly causing side effects by using an oil and fat containing a specific amount of linoleic acid. SOLUTION: This inhibitor of cytokines of interleukin-1β, interleukin-6 and interferon-γ contains an oil and fat containing >=35 wt.% α-linoleic acid. An extract obtained from a leaf, a stem, a root or the like of Labiatae is cited as the oil and fat, and especially the extract is obtained by squeezing seeds of Perilla frutescens crispa, Perilla ocimoides, Linum usitatissimum, linseed or the like. Especially Perilla oils obtained by compressing or extracting the seeds of the Perilla frutescens crispa and the Perilla ocimoides are preferably used. An antiallergic agent is obtained by using the inhibitor as an active ingredient. The medicament can manifest the antiallergic activities by orally administering the medicament, and the daily dose is preferably 600 mg to 10 g expressed in terms of an adult.
Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
The present invention provides adhesion barrier compositions based on a solution of at least one of a biodegradable polyester amide (PEA), polyester urethane (PEUR), or polyester urea (PEU) polymers, dissolved in a biocompatible solvent. The compositions can be applied to a tissue surface, such as in open surgery, as a viscous liquid which forms an adhesive film upon being sprayed or painted onto the tissue surface. Alternatively, the composition can be applied to the tissue surface as a preformed solid layer or double layer (either porous or non-porous) that adheres to the tissue surface. In open surgery, the invention adhesion barrier compositions are used to separate opposing tissue surfaces or tissue-organ surfaces while injured tissues heal, for example in the abdomen or pelvis.     The present invention provides adhesion barrier compositions based on a solution of at least one of a biodegradable polyester amide (PEA), polyester urethane (PEUR), or polyester urea (PEU) polymers, dissolved in a biocompatible solvent. The compositions can be applied to a tissue surface, such as in open surgery, as a viscous liquid which forms an adhesive film upon being sprayed or painted onto the tissue surface. Alternatively, the composition can be applied to the tissue surface as a preformed solid layer or double layer (either porous or non-porous) that adheres to the tissue surface. In open surgery, the invention adhesion barrier compositions are used to separate opposing tissue surfaces or tissue-organ surfaces while injured tissues heal, for example in the abdomen or pelvis.
Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
The Advanced Chronic Disease Self-Management Program (ACDSMP) is a multi-disciplinary, science-based behavior modification program which seeks to empower the patient to manage his own chronic diseases and disorders such as hypertension, asthma, arthritis, obesity, diabetes, heart disease, lung disease and stroke recovery. The program is designed with a breakthrough approach that can help make healthy living become second nature. Healthy eating, walking and better breathing- and staying motivated to continue these - are the building blocks of the program. It involves a combination of eating plan, walking plan, breathing technique and other lifestyle modifications. ACDSMP is a patient centric pro-active approach that works to prevent progression of the chronic disease state and thereby reduce the occurrence of resulting health complications which require expensive acute intervention. Participants are better situated to manage their own conditions and remain healthy for a longer period of time, increasing the ability to maintain independence which will also accordingly decrease the need for long-term care in a residential facility, a great added expense which may be avoided or delayed. This easy-to-follow ACDSMP gives patients the tools they need to manage the challenges of living with a chronic health condition and will result in significant, measurable, and sustainable improvements in health status, self-efficacy, and psychological well-being, along with increasing exercise, reducing fatigue, and enhancing partnership with physicians. The program may also save enough through reductions in healthcare expenditures to pay for itself within the first year based on reducing hospitalizations and outpatient visits.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a lily and anemarrhena decoction, wherein the raw materials of active ingredients comprise: 7 parts by weight of lily and 9 parts by weight of anemarrhena. The production process of the integrated new formulation of lily and anemarrhena decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of lily and anemarrhena decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property, and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of lily and anemarrhena decoction can be realized simultaneously, and the medicament can be separately taken in four time slices according to the midnight-noon ebb-flow and qi and the blood flowing rule of a human body. The integrated new formulation of lily and anemarrhena decoction can be further prepared into films and transdermal agents, which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body, and can be directly absorbed through skin.
A prospective, single arm, open label, multi-center, phase II study of autologous T cells engineered against both CD19 and CD20 antigens for subjects with relapsed or refractory DLBCL after receiving at least two lines of therapy. The investigational agent is the MB-CART2019.1 cells. After successful screening, subjects will undergo leukapheresis to collect product for manufacturing. In preparation for the fresh product infusion, subjects will undergo a lymphodepleting regimen with cyclophosphamide and fludarabine, or bendamustine. Cell infusion will be administered intravenously at a dose of 2.5 x 106 CAR+ cells/kg body weight. The study will start with enrollment of 3 subjects in the lead-in safety phase, and after safety is evaluated, the study will continue with enrollment of the remaining subjects. Subjects will be followed for up to 2 years, for efficacy and safety outcomes as well as health-related quality of life (HRQol). Additional long-term follow-up will be conducted for participants under a separate long-term follow-up protocol.
BACKGROUND: A real-time model for predicting short-term mortality in critically ill patients is needed to identify patients at imminent risk. However, the performance of the model needs to be validated in various clinical settings and ethnicities before its clinical application. In this study, we aim to develop an ensemble machine learning model using routinely measured clinical variables at a single academic institution in South Korea.
METHODS: We developed an ensemble model using deep learning and light gradient boosting machine models. Internal validation was performed using the last two years of the internal cohort dataset, collected from a single academic hospital in South Korea between 2007 and 2021. External validation was performed using the full Medical Information Mart for Intensive Care (MIMIC), eICU-Collaborative Research Database (eICU-CRD), and Amsterdam University Medical Center database (AmsterdamUMCdb) data. The area under the receiver operating characteristic curve (AUROC) was calculated and compared to that for the National Early Warning Score (NEWS).
RESULTS: The developed model (iMORS) demonstrated high predictive performance with an internal AUROC of 0.964 (95% confidence interval [CI] 0.963-0.965) and external AUROCs of 0.890 (95% CI 0.889-0.891) for MIMIC, 0.886 (95% CI 0.885-0.887) for eICU-CRD, and 0.870 (95% CI 0.868-0.873) for AmsterdamUMCdb. The model outperformed the NEWS with higher AUROCs in the internal and external validation (0.866 for the internal, 0.746 for MIMIC, 0.798 for eICU-CRD, and 0.819 for AmsterdamUMCdb; p < 0.001).
CONCLUSIONS: Our real-time machine learning model to predict short-term mortality in critically ill patients showed excellent performance in both internal and external validations. This model could be a useful decision-support tool in the intensive care units to assist clinicians.
PURPOSE:To provide the titled composition giving low stimulation to the body, by compounding ethanol and/or propanol with a food additive selected from polyhydric alcohol, specific amino acid and benzyl benzoate. CONSTITUTION:The objective alcohol composition is prepared by mixing ethanol and/or propanol with one or more compounds selected from (A) a polyhydric alcohol or its derivative permissible as a food additive or a drug additive (e.g. ethylene glycol, propylene glycol, etc.), (B) an amino acid having 1-2 carboxyl groups (e.g. glycine, alanine, etc.) and (C) benzyl benzoate. The addition of the above compounds eliminates the characteristic stimulation of alcohol to the skin and the oral mucosa, keeps the sterilizing effect of alcohol, and exhibits the effect for preventing the dental caries, cleaning the nicotine-stained tooth, and removing the oral odor.